
CompaniesGorat, Yearpur, Ashulia, Dhaka
C2C Pharma Ltd.
0 brands · 25 generics
About C2C Pharma Ltd.
C2C Pharma Ltd. is a new and emerging pharmaceutical company in Bangladesh and a sister concern of Coast to Coast Group. Its manufacturing operation at Gorat, Yearpur, Ashulia, Dhaka is registered with the DGDA under the Allopathic category. The company states that one of its key objectives is to make high-quality and affordable pharmaceutical products accessible to the people who need them.
Company Background and Purpose
C2C Pharma Ltd. is part of Coast to Coast Group, a diversified Bangladeshi group that began its journey in 1991 and operates across sectors including apparel, financial services and pharmaceuticals. The company considers access to quality medicines a fundamental human right and highlights lifelong learning, knowledge and continuous improvement as part of its core values.
What the Allopathic Licence Covers
The Allopathic category refers to the registered pharmaceutical manufacturing category of the manufacturer with the DGDA. In the case of C2C Pharma Ltd., this registration identifies the company as an allopathic pharmaceutical manufacturer; the specific medicines it can manufacture and market depend on applicable product registrations and regulatory approvals. The DGDA maintains separate requirements for drug registration and manufacturing licences, so buyers and procurement teams may consider the registered category and status when evaluating a supplier.
Meaning of the DGDA Status
The supplied DGDA record lists C2C Pharma Ltd. as Functional. In practice, this represents the recorded status of the manufacturer's registration and premises; when evaluating a pharmaceutical supplier, this status should be considered alongside the relevant product registrations and other regulatory requirements.
Registration and Licensing
- DGDA status: Functional
- Licence categories: Allopathic
- DGDA registered address: Gorat, Yearpur, Ashulia, Dhaka
Brands by C2C Pharma Ltd.
No brands are listed for this manufacturer yet.
